Project Grant HT94252510455

This Project Grant award of $620,240 from the National Institute on Deafness and Other Communication Disorders (CFDA 93.173 - Research Related to Deafness and Communication Disorders) supports an observational study examining vestibular pathophysiology and the vestibular implications of standard interventions in patients with sporadic vestibular schwannomas and NF2-related schwannomatosis. The study aims to analyze vestibular dysfunction, its relationship to clinical disability and...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding for the preclinical development of an EYA2 tyrosine phosphatase inhibitor as a potential therapeutic for medulloblastoma, the most common malignant brain tumor in children. The $399,709 award to Sieyax, Inc. (a woman-owned small business) will support two primary objectives: 1) Optimizing the synthesis and evaluating the drug metabolism, pharmacokinetics, and toxicity...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $572,837 to The Leland Stanford Junior University to investigate a novel molecular driver of schwannoma nerve sheath tumors. The research aims to characterize the unique features of schwannomas harboring SOX10 gene mutations, evaluate how these mutations impact chromatin binding and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Mayo Clinic Jacksonville (a nonprofit corporation registered as Scott Lynch MD) to develop a first-in-class non-muscle myosin II (NMII) inhibitor, MT-125, for the treatment of glioblastoma. The $607,634 award, effective January 1, 2025 through December 31, 2029, supports research to uncover the mechanisms behind the synergistic effects of MT-125 when combined with...

This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), provides $319,120 to Vivonics Inc. to develop a portable, wearable device using galvanic vestibular stimulation (GVS) to counteract episodes of vertigo in patients with Meniere's disease. The project aims to demonstrate the feasibility and effectiveness of GVS in suppressing vertigo, with the...

This Project Grant award of $188,169.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The key objectives are to complete proof-of-concept studies evaluating the biological activity and efficacy of the AAV vector in killing cancer cells through in vitro assays and xenograft mouse models. The...

The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $219,351 Project Grant (R21CA296696) to The Institute for Cancer Research (ICR) to assess the efficacy and toxicity of T3 (the active form of thyroid hormone) for the treatment of medulloblastoma, the most common malignant brain tumor in children. The research aims to evaluate the toxicity, pharmacokinetics, and pharmacodynamics of T3 in tumor-bearing mice, as well as examine...

This federal Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under CFDA program 93.173 "Research Related to Deafness and Communication Disorders", provides $265,410 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for a research project titled "Defining the Role of MET Components in Vestibular Hair Cell Maturation and Gene Therapy Responsiveness". The project aims to better...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $235,707 to Weill Medical College of Cornell University to conduct research on the use of [68Ga]-DOTATATE PET/MRI imaging to improve diagnostic accuracy, increase understanding of pituitary neuroendocrine tumor (PitNET) biology, and optimize stereotactic radiosurgery (SRS) targeting for residual/recurrent PitNET. The research aims to characterize the range of...

This $659,164 Project Grant awarded by the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), aims to identify pharmacological modulators, endogenous ligands, and binding partners for the orphan G protein-coupled receptor GPR156. The grant, awarded to the University of Rochester, will leverage innovative cell-based assays and proximity-mediated labeling technologies to discover new...